Asset Purchase Agreement - MedStrong International Corp. and Joseph R. Andrade
October 24, 2003
Joseph R. Andrade, M.D.
131 Fox Meadow Drive
Scarsdale, New York 10583
Dear Dr. Andrade:
Subject to the terms and conditions set forth below, we are pleased to propose
the following transaction between MedStrong International Corporation ("Buyer")
and you in your individual capacity ("Seller").
I. CLOSING DATE
------------
The closing date (the "Closing Date") shall occur on such date as the parties
hereto shall mutually agree; provided, however, that the Closing Date shall not
occur later than March 15, 2004.
II. TRANSACTION
-----------
On the Closing Date,
(A) Seller shall sell, assign, transfer and convey to Buyer all of Seller's
right, title and interest in and to (i) that certain aerosol holding chamber
for use with a metered dose inhaler invented by Seller (the "Product"), and
(ii) United States Patents numbered 5,855,202 and 6,240,917 and any
subsequent patents issued to Seller with respect to the Product
(collectively, the "Patents") (the Product and the Patents being hereinafter
referred to as the "Assets"); and
(B) Buyer shall purchase and acquire all of Seller's right, title and interest
in and to, and (except as otherwise expressly provided) assume all of
Seller's obligations with respect to, the Assets.
PURCHASE PRICE
(A) In consideration for the sale described in Paragraph II(A) above, and
assuming that all conditions precedent have been satisfied, on the Closing
Date Buyer shall pay to Seller the purchase price ("Purchase Price") in the
amount of Twenty Five Thousand Dollars ($25,000).
(B) In addition to the Purchase Price payable on the Closing Date, Buyer will
pay Seller Twenty Percent (20%) of (i) any royalty Buyer may receive from
the ultimate manufacturer of the Product and (ii) any "front money" or other
tangible benefit Buyer may receive from the ultimate manufacturer
inconsideration for entering into a long-term production/distribution
agreement (the "Royalty").
The Purchase Price and/or the Royalty may be subject to adjustment in the
event that (i) due diligence discloses any material variation from the
assumptions upon which the parties have based their calculation of the
Purchase Price or (ii) one or more conditions precedent remain unsatisfied
as of the
<PAGE>
Closing Date and, notwithstanding the same, the parties mutually agree to
consummate the transaction contemplated hereunder.
IV. CONDITIONS PRECEDENT
--------------------
(A) Buyers' obligation to pay the Purchase Price and to take such other actions
as may be necessary to consummate the transaction contemplated hereunder is
subject to satisfaction of each of the following conditions precedent on or
before the Closing Date:
(i) Buyer shall be satisfied that Seller has the ability to transfer,
sell and assign complete interest the Assets free and clear of any
competing claims or other encumbrances whatsoever;
(ii) Buyer shall be satisfied, in its sole and absolute discretion, that
a market exists for the Product and that the market is of a size
sufficient to make production and distribution of the Product
economically feasible;
(iii)Seller shall have agreed to make himself available to Buyer, upon
reasonable notice, to participate in meetings and/or presentations
requiring demonstration of, or technical discussion with respect to,
the Product; provided that the reasonable expenses of Seller shall
be reimbursed by Buyer;
(iv) Seller and Buyer shall have agreed upon a
non-competition/non-circumvention clause of reasonable scope and
duration;
(v) Buyer shall have received such evidence as it may reasonably require
that Seller has obtained all consents and approvals necessary to
enable him to consummate the transaction contemplated hereunder; and
(vi) Buyer shall have received usual and customary representations from
Seller.
(B) Seller's obligation to make the sale, assignment, transfer and conveyance
described in Paragraph II(A) above and to take such other actions as may be
necessary to consummate the transaction contemplated hereunder is subject to
satisfaction of each of the following conditions precedent on or before the
Closing Date:
(i) Buyer shall have available for delivery to Sellers in same day funds
the full amount of the Purchase Price;
(ii) Seller shall have received such evidence as it may reasonably
require that Buyer has obtained all consents and approvals necessary
to enable it to consummate the transaction contemplated hereunder;
and
(iii)Seller shall have received usual and customary representations from
Buyer.
V. INDEMNIFICATION
---------------
(A) Each party hereto shall bear its own costs and expenses with respect to the
negotiation and consummation of the transaction contemplated hereunder;
provided, however, that should either party fail to negotiate in good faith
to effect the consummation of the transaction contemplated hereunder, such
party shall fully indemnify the other for all such costs and expenses.
<PAGE>
(B) Seller shall indemnify and hold harmless Buyer from and against any and all
debts, claims, liabilities, damages and obligations (and related costs and
expenses) arising out of or in any way related to (i) any act, omission or
misrepresentation of Seller, or (ii) the Assets prior to the Closing Date.
(C) Buyer shall indemnify and hold harmless Seller from and against any and all
debts, claims, liabilities, damages and obligations (and related costs and
expenses) arising out of or in any way related to (i) any act, omission or
misrepresentation of Buyer or any of Buyer's officers, employees or agents,
or (ii) the Assets subsequent to the Closing Date.
VI. DUE DILIGENCE
-------------
Seller shall make available to Buyer at reasonable times upon reasonable notice
such of its personnel and files, records and other documents as Buyer shall
reasonably require in order to confirm the representations that have been made
by Seller with respect to the Assets and the assumptions upon which Buyer has
based its calculation of the Purchase Price and the Royalty. In the event that
such due diligence reveals any material variation from such representations and
assumptions, Buyer may elect to (i) terminate its participation in this
transaction without further obligation to the Seller, or (ii) propose an
adjusted Purchase Price or Royalty and/or other modifications to the transaction
that Seller may accept or reject in its sole discretion.
VII. DOCUMENTATION
-------------
The obligations of each party with respect to the transaction contemplated
hereunder shall be subject to, and conditioned upon, the execution and delivery
of definitive documentation acceptable to each party. Unless otherwise agreed
to, the preparation of such documentation shall be the responsibility of Buyer.
VIII. CONFIDENTIALITY
---------------
Unless otherwise agreed to by Buyer, Seller shall make no public announcement or
other disclosure in any way relating to this proposed transaction to any person
including, but not limited to, the Retailers, Service Contract holders and
Sellers' employees and suppliers.
IX. ENFORCEABILITY
--------------
Notwithstanding anything to the contrary set forth herein, Buyer's obligation to
consummate the transaction described herein shall be subject to (i) negotiation
of acceptable documentation, (ii) approval of the transaction by its Board of
Directors and (iii) satisfactory completion of its due diligence as described in
Paragraph VI.
X. GOVERNING LAW
-------------
This letter of intent shall be governed by and construed in accordance with the
laws of the State of New York .
<PAGE>
If the forgoing is acceptable to you, please execute and return the enclosed
copy of this letter.
Sincerely,
MEDSTRONG INTERNATIONAL CORPORATION
By:
------------------------
Name:
Title:
Agreed to and accepted this 24th day of October, 2003.
------------------------------
Joseph R. Andrade, M.D.